Why Innoviva’s latest earnings matter for shareholders

Innoviva (INVA) just posted fourth quarter and full year 2025 results, highlighted by higher revenue, a sharp jump in net income, new product approvals, and a sizeable share repurchase plan.

These numbers land as the company pushes further into hospital and critical care markets, giving investors fresh information on how its shift from a royalty focused model is progressing and how management is choosing to return capital.

Innoviva’s share price has climbed 8.34% over the past month and 14.39% year to date. Its 1 year total shareholder return of 29.07% and 3 year total shareholder return above 100% highlight momentum that recent earnings, product approvals and the new repurchase plan have kept in focus.

If this earnings update has you thinking about where the next move in healthcare could come from, take a look at 31 healthcare AI stocks as a starting list of ideas.

With Innoviva trading at US$22.73, alongside a reported intrinsic value gap and sizeable analyst price target discount, the key question is whether the recent earnings strength is still underappreciated or whether the market is already pricing in potential future developments.

Price-to-Earnings of 6.2x: Is it justified?

At a last close of $22.73, Innoviva is trading on a P/E of 6.2x, which screens as inexpensive compared to both the US pharmaceuticals industry and its peer group.

The P/E ratio compares the current share price to earnings per share and gives a quick sense of how much the market is paying for current profits. For a profitable biopharma name like Innoviva, it is a straightforward way to see how current earnings are being valued while the business shifts from a royalty focused model toward a broader hospital and critical care portfolio.

Here, the gap is wide. The stock trades at 6.2x earnings, while the US pharmaceuticals industry average sits at 19.5x and the peer average at 14x. Against the estimated fair P/E of 12.3x from the SWS fair ratio model, the current multiple is also well below a level the market could move towards if sentiment or earnings quality aligned more closely with that benchmark. Earnings growth over the past year has been very large compared with both Innoviva’s own five year trend and the wider industry, although investors also need to factor in the impact of large one off items on those results.

Result: Price-to-Earnings of 6.2x (UNDERVALUED)

However, you also need to weigh risks like an annual net income decline of 3% and how quickly newer hospital products can offset any slowdown in the royalty portfolio.

Another view on value: DCF vs earnings multiple

While the 6.2x P/E suggests a low price for Innoviva’s current earnings, our DCF model presents a different perspective on value. On that framework, the estimated future cash flow value is $54.47 per share versus the current $22.73, indicating a wide gap that may or may not close over time.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Innoviva for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 47 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Does this mix of low P/E, DCF upside, risks and rewards feel compelling or cautious to you? Act while the details are fresh and weigh both sides with 3 key rewards and 3 important warning signs.

Looking for more investment ideas?

If this update has sharpened your thinking, do not stop at one company. Use a few focused stock lists to pressure test your view and spot fresh opportunities.

• Target quality at a discount by reviewing 47 high quality undervalued stocks that pair stronger fundamentals with lower prices than many investors might expect.
• Steady your portfolio by checking 77 resilient stocks with low risk scores that score well on resilience so short term swings are less likely to unsettle your plan.
• Get ahead of the crowd with a screener containing 24 high quality undiscovered gems that most investors are not watching yet but already show solid financial traits.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.